Olux is a drug owned by Norvium Bioscience Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 01, 2016. Details of Olux's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6126920 | Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition |
Mar, 2016
(8 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Olux is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Olux's family patents as well as insights into ongoing legal events on those patents.
Olux's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Olux's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 01, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Olux Generic API suppliers:
Clobetasol Propionate is the generic name for the brand Olux. 35 different companies have already filed for the generic of Olux, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Olux's generic
How can I launch a generic of Olux before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Olux's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Olux's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Olux -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.0005 | 27 Jun, 2005 | 1 | 10 Mar, 2008 | 03 Oct, 2017 | Eligible |
Alternative Brands for Olux
Olux which is used for treating skin diseases using a corticosteroid-containing pharmaceutical composition., has several other brand drugs in the same treatment category and using the same active ingredient (Clobetasol Propionate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Norvium Bioscience |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Clobetasol Propionate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Eyenovia |
| |
| Galderma Labs |
| |
| Galderma Labs Lp |
| |
| Norvium Bioscience |
| |
| Primus Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Clobetasol Propionate, Olux's active ingredient. Check the complete list of approved generic manufacturers for Olux
About Olux
Olux is a drug owned by Norvium Bioscience Llc. It is used for treating skin diseases using a corticosteroid-containing pharmaceutical composition. Olux uses Clobetasol Propionate as an active ingredient. Olux was launched by Norvium Bioscience in 2000.
Approval Date:
Olux was approved by FDA for market use on 26 May, 2000.
Active Ingredient:
Olux uses Clobetasol Propionate as the active ingredient. Check out other Drugs and Companies using Clobetasol Propionate ingredient
Treatment:
Olux is used for treating skin diseases using a corticosteroid-containing pharmaceutical composition.
Dosage:
Olux is available in aerosol, foam form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.05% | AEROSOL, FOAM | Discontinued | TOPICAL |